US5858980A
(en)
*
|
1990-03-30 |
1999-01-12 |
Autoimmune, Inc. |
Peptide fragments of myelin basic protein
|
US7090982B2
(en)
|
1991-10-22 |
2006-08-15 |
The Governors Of The University Of Alberta |
Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
|
US6252040B1
(en)
|
1991-10-22 |
2001-06-26 |
The Governors Of The University Of Alberta |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
|
US5800808A
(en)
|
1994-05-24 |
1998-09-01 |
Veda Research And Development Co., Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
US5858964A
(en)
*
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
IL119989A0
(en)
*
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
EP1054880A1
(en)
*
|
1998-02-13 |
2000-11-29 |
Autoimmune, Inc. |
TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
|
WO2000005250A1
(en)
|
1998-07-23 |
2000-02-03 |
Yeda Research And Development Co., Ltd |
Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
|
ES2527760T3
(es)
*
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
EP1105414A2
(en)
|
1998-07-23 |
2001-06-13 |
President And Fellows of Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
CA2794705C
(en)
|
1998-09-25 |
2017-07-18 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
WO2000020010A1
(en)
*
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
US7083777B1
(en)
|
1999-04-02 |
2006-08-01 |
The Brigham And Women's Hospital, Inc. |
Immunomodulating polymers
|
ATE302020T1
(de)
*
|
2000-01-20 |
2005-09-15 |
Yeda Res & Dev |
Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
|
US7022663B2
(en)
*
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
JP2003522799A
(ja)
*
|
2000-02-18 |
2003-07-29 |
イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス |
コポリマー1の経口、経鼻および経肺投与製剤
|
US20020077278A1
(en)
*
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
IL153236A0
(en)
*
|
2000-06-05 |
2003-07-06 |
Teva Pharma |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
JP4328090B2
(ja)
*
|
2000-06-07 |
2009-09-09 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
神経細胞の保護療法におけるコポリマー1、関連ペプチドおよびポリペプチドならびにそれらによって処理されたt細胞の使用
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
IL148202A0
(en)
*
|
2000-06-20 |
2002-09-12 |
Caprion Pharmaceuticals Inc |
Copolymers and methods of treating prion-related diseases
|
IL137460A0
(en)
*
|
2000-07-24 |
2001-07-24 |
Yeda Res & Dev |
Identifying antigen clusters for monitoring a global state of an immune system
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
SV2003000753A
(es)
|
2000-12-05 |
2003-06-16 |
Brigham & Womens Hospital |
Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
|
GB2369896A
(en)
|
2000-12-06 |
2002-06-12 |
Marconi Comm Ltd |
Tunable optical filter actuator
|
KR100442122B1
(ko)
*
|
2001-07-31 |
2004-07-30 |
한국전기연구원 |
영구 자석을 이용한 브러시리스 발전기
|
PT1459065E
(pt)
*
|
2001-12-04 |
2010-10-11 |
Teva Pharma |
Processos para a medição da potência do acetato de glatirâmero
|
IL160105A0
(en)
*
|
2001-12-06 |
2004-06-20 |
Yeda Res & Dev |
Vaccine for treatment of motor neurone diseases
|
AU2002360696A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Ilex Oncology, Inc. |
Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
|
AU2004203772B2
(en)
|
2003-01-07 |
2009-07-16 |
Yeda Research And Development Co. Ltd. |
Eye-drop vaccine containing copolymer 1 for therapeutic immunization
|
PT1592384E
(pt)
*
|
2003-01-21 |
2013-01-28 |
Yeda Res & Dev |
Cop-1 para o tratamento de doenças inflamatórias do intestino
|
EP1603530A1
(en)
*
|
2003-03-04 |
2005-12-14 |
Teva Pharmaceutical Industries Limited |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
CA2520865A1
(en)
|
2003-03-31 |
2004-10-21 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic immunomodulators for the treatment of asthma and allergy
|
WO2005056574A2
(en)
|
2003-12-09 |
2005-06-23 |
Yeda Research And Development Co. Ltd. |
Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
|
WO2005041933A1
(en)
*
|
2003-10-31 |
2005-05-12 |
Teva Pharmaceutical Industries, Ltd. |
Nanoparticles for drug delivery
|
US20080085269A1
(en)
|
2003-11-12 |
2008-04-10 |
Michal Eisenbach-Schwartz |
Vaccine And Method For Treatment Of Neurodegenerative Diseases
|
AU2005211424A1
(en)
*
|
2004-02-02 |
2005-08-18 |
Mixture Sciences, Inc. |
Peptide mixtures with immunomodulatory activity
|
KR20060125916A
(ko)
*
|
2004-03-01 |
2006-12-06 |
펩팀문, 인코포레이티드 |
자가면역 질병을 치료하기 위한 방법 및 조성물
|
US20070244056A1
(en)
*
|
2004-03-03 |
2007-10-18 |
Liat Hayardeny |
Combination Therapy With Glatiramer Acetate and Riluzole
|
US20050260770A1
(en)
*
|
2004-04-01 |
2005-11-24 |
Cohen Irun R |
Antigen array and diagnostic uses thereof
|
RU2410115C2
(ru)
|
2004-05-07 |
2011-01-27 |
Пептиммьюн, Инк. |
Способы лечения заболеваний с помощью статистических сополимеров
|
US20060194725A1
(en)
*
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
US7655221B2
(en)
*
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
RU2387453C2
(ru)
|
2004-06-25 |
2010-04-27 |
АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК |
Композиции и способы лечения неврологических нарушений
|
DK1797109T3
(en)
*
|
2004-09-09 |
2016-04-11 |
Yeda Res & Dev |
MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
|
EP2177528B1
(en)
*
|
2004-09-09 |
2011-12-07 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
|
US8324641B2
(en)
*
|
2007-06-29 |
2012-12-04 |
Ledengin, Inc. |
Matrix material including an embedded dispersion of beads for a light-emitting device
|
DE602005016292D1
(de)
*
|
2004-10-29 |
2009-10-08 |
Sandoz Ag |
Verfahren zur herstellung von glatiramer
|
WO2006057003A2
(en)
*
|
2004-11-29 |
2006-06-01 |
Yeda Research And Development Co. Ltd. |
Induction of neurogenesis and stem cell therapy in combination with copolymer 1
|
EP1838326A4
(en)
*
|
2005-02-02 |
2009-09-30 |
Teva Pharma |
PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS
|
PT1848415E
(pt)
*
|
2005-02-17 |
2013-06-27 |
Teva Pharma |
Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
|
US20100167983A1
(en)
*
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
EP1891233A4
(en)
*
|
2005-04-25 |
2010-03-24 |
Yeda Res & Dev |
MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
|
WO2007081975A2
(en)
*
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
US8206726B2
(en)
|
2006-02-06 |
2012-06-26 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic polysaccharides for promotion of immune system maturation and health
|
AU2007238595A1
(en)
|
2006-04-13 |
2007-10-25 |
Peptimmune, Inc. |
Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
|
WO2007127977A2
(en)
|
2006-04-28 |
2007-11-08 |
Momenta Pharmaceuticals, Inc. |
Methods of evaluating peptide mixtures
|
KR100831796B1
(ko)
*
|
2006-05-29 |
2008-05-28 |
엘지전자 주식회사 |
타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
|
JP5412280B2
(ja)
|
2006-06-28 |
2014-02-12 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
加齢性黄斑変性症の治療法
|
ATE452140T1
(de)
*
|
2006-07-05 |
2010-01-15 |
Momenta Pharmaceuticals Inc |
Verbessertes verfahren zur herstellung von copolymer-1
|
CN101743470A
(zh)
|
2007-06-21 |
2010-06-16 |
动量制药公司 |
共聚物测定
|
US20090029766A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Lutnick Howard W |
Amusement gaming access and authorization point
|
CA2705046C
(en)
*
|
2007-07-31 |
2015-03-03 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
KR20170075026A
(ko)
|
2007-10-16 |
2017-06-30 |
펩팀문, 인코포레이티드 |
에피토프의 지정 확장에 의해 지정 서열 중합체 조성물을 포함하는 백신을 설계하고 제조하는 방법
|
WO2009062132A2
(en)
|
2007-11-09 |
2009-05-14 |
California Institute Of Technology |
Immunomodulating compounds and related compositions and methods
|
CA2702437C
(en)
*
|
2007-11-28 |
2013-06-25 |
Teva Pharmaceutical Industries Ltd. |
Method of delaying the onset of clinically definite multiple sclerosis
|
ES2449865T5
(es)
*
|
2008-04-16 |
2022-11-18 |
Momenta Pharmaceuticals Inc |
Análisis de composiciones de copolímeros de aminoácidos
|
PL2307448T3
(pl)
*
|
2008-08-07 |
2015-10-30 |
Sigma Aldrich Co Llc |
Wytwarzanie polilizyny i poliornityny o małym ciężarze cząsteczkowym z wysoką wydajnością
|
WO2010017292A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Scinopharm Taiwan, Ltd. |
Synthesis of glatiramer acetate
|
AR074881A1
(es)
|
2008-12-24 |
2011-02-16 |
Synthon Bv |
Un proceso para purificar una mezcla de polimeros
|
US8859489B2
(en)
*
|
2009-04-03 |
2014-10-14 |
Momenta Pharmaceuticals, Inc. |
Water-mediated control of depolymerization step of glatiramer acetate synthesis
|
AU2009347384B2
(en)
*
|
2009-06-04 |
2014-10-23 |
Council Of Scientific & Industrial Research |
A process for the preparation of copolymer - 1 (Cop-I), composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine-drug for the treatment of multiple sclerosis
|
ES2383347T3
(es)
|
2009-07-15 |
2012-06-20 |
Teva Pharmaceutical Industries, Ltd. |
Formulación de volumen reducido de acetato de glatirámero y procedimientos de administración
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
US8691790B2
(en)
*
|
2009-07-27 |
2014-04-08 |
James Layne Boucher |
Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
|
DE202010018377U1
(de)
|
2009-08-20 |
2016-02-25 |
Yeda Research And Development Co., Ltd. |
Niedrigfrequente therapie mit glatirameracetat
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
ES2699692T3
(es)
|
2010-01-04 |
2019-02-12 |
Mapi Pharma Ltd |
Sistema de depósito que comprende acetato de glatiramer
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
US20130035390A1
(en)
|
2010-01-13 |
2013-02-07 |
Ramot At Tel-Aviv University Ltd. |
Treatment of multiple sclerosis
|
US8759302B2
(en)
*
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
EP2555753B1
(en)
|
2010-04-07 |
2018-08-01 |
California Institute of Technology |
Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
|
EP2563804A4
(en)
*
|
2010-04-27 |
2014-09-17 |
Reddys Lab Ltd Dr |
PREPARATION OF POLYPEPTIDES AND THEIR SALTS
|
EP2571982A4
(en)
|
2010-05-20 |
2014-01-01 |
California Inst Of Techn |
ANTIGEN-SPECIFIC TREGS AND CORRESPONDING COMPOSITIONS, METHODS AND SYSTEMS
|
US9109006B2
(en)
*
|
2010-07-29 |
2015-08-18 |
Santhanakrishnan Srinivasan |
Glatiramer acetate molecular weight markers
|
EA025780B1
(ru)
|
2010-10-11 |
2017-01-30 |
Тева Фармасьютикал Индастриз Лтд. |
Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
|
US9029507B2
(en)
|
2011-02-14 |
2015-05-12 |
Usv Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
EP2699317B1
(en)
*
|
2011-04-21 |
2016-08-10 |
Mapi Pharma Limited |
Random pentapolymer for treatment of autoimmune diseases
|
US20140348861A1
(en)
|
2011-05-05 |
2014-11-27 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
WO2013009885A2
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Evaluation of copolymer diethylamide
|
WO2013009864A1
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Structure assessment of heterogeneous polypeptide mixtures
|
WO2013009945A1
(en)
|
2011-07-12 |
2013-01-17 |
The Brigham And Women's Hospital, Inc. |
Lipid-containing psa compositions, methods of isolation and methods of use thereof
|
US8575198B1
(en)
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
KR20140101730A
(ko)
|
2011-10-10 |
2014-08-20 |
테바 파마슈티컬 인더스트리즈 리미티드 |
글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
|
WO2013139728A1
(en)
|
2012-03-19 |
2013-09-26 |
Synthon Bv |
Glatiramer acetate human monocyte cell-based potency assay
|
EP2642290A1
(en)
|
2012-03-19 |
2013-09-25 |
Synthon BV |
Glatiramer acetate human monocytic cell line-based potency assay
|
US20140045740A1
(en)
*
|
2012-08-13 |
2014-02-13 |
Momenta Pharmaceuticals, Inc. |
Analysis of glatiramer acetate
|
US9617596B2
(en)
|
2012-10-10 |
2017-04-11 |
Teva Pharmaceutical Industries, Ltd. |
Biomarkers predictive for clinical response for glatiramer acetate
|
WO2014060942A2
(en)
*
|
2012-10-20 |
2014-04-24 |
Mahesh Kandula |
Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
PT2774640E
(pt)
|
2013-03-08 |
2015-02-09 |
Teva Pharma |
Dispositivo injector reutilizável para seringa
|
PT2774639E
(pt)
|
2013-03-08 |
2015-01-13 |
Teva Pharma |
Dispositivo injector reutilizável para seringa
|
JP6553018B2
(ja)
|
2013-03-14 |
2019-07-31 |
マイラン・インコーポレイテッドMylan Inc. |
酢酸グラチラマー応答バイオマーカーmRNA効力アッセイ
|
WO2014173463A1
(en)
|
2013-04-26 |
2014-10-30 |
Synthon Bv |
Glatiramer acetate human monocytic cell line-based potency assay
|
EP2994161B1
(en)
|
2013-05-10 |
2020-10-28 |
California Institute of Technology |
Probiotic prevention and treatment of colon cancer
|
CN103265624B
(zh)
*
|
2013-05-27 |
2015-04-22 |
成都圣诺生物制药有限公司 |
格拉替雷的制备方法
|
CN104371012A
(zh)
*
|
2013-08-12 |
2015-02-25 |
深圳翰宇药业股份有限公司 |
一种合成醋酸格拉替雷的方法
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
EP3060684A4
(en)
|
2013-10-24 |
2017-06-07 |
Mylan Inc. |
Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
|
US10545144B2
(en)
|
2013-12-31 |
2020-01-28 |
Yeda Research And Development Co., Ltd. |
Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
|
JP6903432B2
(ja)
|
2014-03-12 |
2021-07-14 |
イエダ リサーチ アンド ディベロップメント カンパニー リミテッド |
Cnsの疾患および傷害を処置するために全身性調節性t細胞のレベルまたは活性を低下させること
|
CN104844697B
(zh)
|
2014-09-26 |
2018-10-23 |
深圳翰宇药业股份有限公司 |
醋酸格拉替雷的制备方法
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
CN107533058A
(zh)
|
2015-03-01 |
2018-01-02 |
免疫阵列有限公司 |
使用蛋白、肽和寡核苷酸抗原诊断系统性红斑狼疮
|
US11331335B2
(en)
|
2015-06-10 |
2022-05-17 |
California Institute Of Technology |
Sepsis treatment and related compositions methods and systems
|
CN108135167B
(zh)
|
2015-08-19 |
2021-07-09 |
哈佛学院院长及董事 |
脂化psa组合物和方法
|
ES2744179T3
(es)
|
2015-09-24 |
2020-02-24 |
Chemi Spa |
Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas
|
ES2707500T3
(es)
|
2015-11-23 |
2019-04-03 |
Chemi Spa |
Análisis mediante RP-HPLC de mezclas de polipéptidos complejos
|
CN107522774B
(zh)
*
|
2016-06-22 |
2021-07-02 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
|
WO2018002930A1
(en)
|
2016-06-30 |
2018-01-04 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
CA3030974A1
(en)
|
2016-07-15 |
2018-01-18 |
President And Fellows Of Harvard College |
Glycolipid compositions and methods of use
|
MX2019001999A
(es)
|
2016-08-28 |
2019-08-29 |
Mapi Pharma Ltd |
Proceso para la preparacion de microparticulas que contienen acetato de glatiramer.
|
HRP20230738T1
(hr)
|
2016-08-31 |
2023-10-27 |
Mapi Pharma Ltd |
Depo sustavi koji sadrže glatiramer acetat
|
WO2018178973A1
(en)
|
2017-03-26 |
2018-10-04 |
Mapi Pharma Ltd. |
Glatiramer depot systems for treating progressive forms of multiple sclerosis
|
JP7000458B2
(ja)
|
2017-05-15 |
2022-02-10 |
ステム セル メディスン リミテッド |
長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療
|
JP2020519645A
(ja)
|
2017-05-15 |
2020-07-02 |
ステム セル メディスン リミテッド |
脂肪組織由来幹細胞による多発性硬化症の治療
|
EP3765034A1
(en)
|
2018-03-12 |
2021-01-20 |
Yeda Research and Development Co. Ltd |
Treatment of a heart disease
|